Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele

Neurology

Volumn 62, Issue 11, 2004, Pages 1990-1995

  Caselli, Richard J ^a,b   Reiman, E M ^a,c   Osborne, D ^a,b   Hentz, J G ^a,b   Baxter, L C ^a,d   Hernandez, J L ^a,b   Alexander, G G ^a,e  

^a Department of Neurology ^*  (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; AMNESIA; APOE GENE; ARTICLE; BEHAVIOR; COGNITION; COGNITIVE DEFECT; FEMALE; GENE; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RECALL;

EID: 2942566453     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000129533.26544.BF     Document Type: Article

References (33)

1. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
2. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
3. Baxter LC, Caselli RJ, Johnson SC, Reiman EM, Osborne D. Apolipoprotein E e4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. Neurobiol Aging 2004 (in press).
4. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990;31:545-548.
5. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and education level. JAMA 1993;269:2386-2391.
6. Lezak MD. Neuropsychological assessment, 2nd edition. New York: Oxford University Press, 1983.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition, revised. Washington, DC: American Psychiatric Association, 1987.
8. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change-report of a National Institute of Mental Health work group. Dev Neuropsychol 1986;2:261-276.
9. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition. Washington, DC: American Psychiatric Association, 1994.
12. Morey LC. Personality Assessment Inventory. Professional manual. Odessa, FL: Psychological Assessment Resources, 1991.
13. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-947.
14. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of a genetic risk factor for Alzheimer's disease in apolipoprotein E type 4 homozygotes using positron emission tomography. N Engl J Med 1996;334:752-758.
15. Troncoso JC, Cataldo AM, Nixon RA, et al. Neuropathology of preclinical and clinical late onset Alzheimer's disease. Ann Neurol 1998;43:673-676.
16. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E e4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 1998;153:152-155.
17. Smith CD, Andersen AH, Kryscio RJ, et al. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 1999;53:1391-1396.
18. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000;343:450-456.
19. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E e4 heterozygotes: a foundation for testing Alzheimer's dementia prevention therapies. Proc Natl Acad Sci USA 2001;98:3334-3339.
20. Caselli RJ, Graff-Radford NR, Reiman EM, et al. Preclinical memory decline in cognitively normal apolipoprotein E-ε4 homozygotes. Neurology 1999;53:201-207.
21. Caselli RJ, Osborne D, Reiman EM, et al. Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. J Neurol Sci 2001;189:93-98.
22. Caselli RJ, Reiman EM, Hentz JG, Osborne D, Alexander GE, Boeve BF. A distinctive interaction between memory and chronic daytime somnolence in asymptomatic APOE e4 homozygotes. Sleep 2002;25:447-453.
23. Caselli RJ, Reiman EM, Hentz JG, Osborne D, Alexander GE. A distinctive interaction between chronic anxiety and problem solving in APOE e4 homozygotes. J Neuropsychiatry Clin Neurosci 2004 (in press).
24. Mauricio M, O'Hara R, Yesavage JA, et al. A longitudinal study of apolipoprotein E genotype and depressive symptoms in community dwelling older adults. Am J Geriatr Psychiatry 2000;8:196-200.
25. Harwood DG, Barker WW, Ownby RL, Mullan M, Duara R. Factors associated with depressive symptoms in non-demented community dwelling elderly. Int J Geriatr Psychiatry 1999;14:331-337.
26. Papassotiropoulos A, Bagli M, Jessen F, Rao ML, Schwab SG, Heun R. Early onset and late onset depression are independent of the genetic polymorphism of apolipoprotein E. Dement Geriatr Cogn Disord 1999;10:258-261.
27. Forsell Y, Corder EH, Basun H, Lannfelt L, Viitanen M, Winblad B. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+. Biol Psychiatry 1997;42:898-903.
28. Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner JC. A twin study of late onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Biol Psychiatry 1997;41:851-856.
29. Li YS, Meyer JS, Thornby J. Longitudinal follow-up of depressive symptoms among normal versus cognitively impaired elderly. Int J Geriatr Psychiatry 2001;16:718-727.
30. Friedland RP, Fritsch T, Smyth KA, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci USA 2001;98:3440-3445.
31. Scarmeas N, Levy G, Tang MX, Manly J, Stern Y. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology 2001;57:2236-2242.
32. Wilson RS, Mendes De Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer's disease. JAMA 2002;287:742-748.
33. Wilson RS, Bennett DA, Bienias JL, et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002;59:1910-1914.